Protocol Ledger

NCT05593575 · Phase II · COMPLETED

Efficacy and Safety of SPH3127 Tablets on Treating the Diabetic Kidney Disease

Interventional Phase II clinical trial protocol NCT05593575 sponsored by Shanghai Pharmaceuticals Holding Co in Endocrinology, Obesity, and Metabolic, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2023-03-22 Enrollment: 305 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT05593575
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)305 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT05593575
Protocol FieldVerified Registry Value
NCT IdentifierNCT05593575
Consolidated Lead SponsorShanghai Pharmaceuticals Holding Co
Therapeutic Condition CohortEndocrinology, Obesity, and Metabolic
Clinical Trial PhasePhase II
Overall Recruitment StatusCOMPLETED
Registered Enrollment305 participants (ACTUAL)
Registered Start Date2023-03-22
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Endocrinology, Obesity, and Metabolic Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI